Cancer, Pediatric low-grade glioma
DAWNDay One PharmaceuticalsCatalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for OJEMDA™ (Tovorafenib) (DAY101) in Cancer, Pediatric low-grade glioma . The expected timing is based on the latest available company guidance and may change.
FIREFLY-2 trial; as front-line therapy in 6mos - 25 yrs old. 1/13/25- Enrollment ongoing; over 100 sites activated globally, complete by H1 2026. 11/04/25:- Enrollment in the pivotal Ph3 FIREFLY-2 trial is progressing, with completion still anticipated in H1 2026. 01/11/26:- FIREFLY-2 enrollment targeted for H1 2026; mid-2027 Ph3 data readout, supporting potential 2028 approval. 02/24/26:- FIREFLY-2 enrollment remains on track, with full enrollment still anticipated in H1 2026.
Verification
Confirm timing and program details against the company announcement or filing.